Bicara Therapeutics BCAX Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's share based compensation arrangement by share based payment award fair value assumptions risk free interest rate.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Bicara Therapeutics's share based compensation arrangement by share based payment award fair value assumptions risk free interest rate?
- Bicara Therapeutics (BCAX) reported share based compensation arrangement by share based payment award fair value assumptions risk free interest rate of 3.8% in Q4 2024.
- What does share based compensation arrangement by share based payment award fair value assumptions risk free interest rate mean?
- The risk-free rate is an input used in option pricing models, typically based on the yield of government bonds with a maturity matching the expected term of the stock options. It represents the theoretical return on an investment with zero risk. This metric is essential for valuing employee stock-based compensation and understanding the assumptions behind equity-based expenses.